ProfileGDS5678 / 1423134_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 82% 80% 80% 84% 82% 81% 81% 81% 81% 79% 80% 84% 79% 80% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.8639982
GSM967853U87-EV human glioblastoma xenograft - Control 25.7029480
GSM967854U87-EV human glioblastoma xenograft - Control 35.6142680
GSM967855U87-EV human glioblastoma xenograft - Control 46.4549684
GSM967856U87-EV human glioblastoma xenograft - Control 55.9997382
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.6555681
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.6986681
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.7679881
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.8096681
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.6101879
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.6460280
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.2864684
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.5241479
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.6777880